{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:53:39Z","timestamp":1787928819477,"version":"build-2784847793"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/aps.2015.30","type":"journal-article","created":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T09:02:33Z","timestamp":1433754153000},"page":"841-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data"],"prefix":"10.1038","volume":"36","author":[{"given":"Jie-mei","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-lan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-bo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-qiu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-zhen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"BFaps201530_CR1","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344\u201352.","journal-title":"JAMA"},{"key":"BFaps201530_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83\u201391.","journal-title":"Osteoporos Int"},{"key":"BFaps201530_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333\u201340.","journal-title":"N Engl J Med"},{"key":"BFaps201530_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103\u201311.","journal-title":"Calcif Tissue Int"},{"key":"BFaps201530_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00198-012-2056-0","volume":"24","author":"MR McClung","year":"2013","unstructured":"McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, et al. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int 2013; 24: 293\u20139.","journal-title":"Osteoporos Int"},{"key":"BFaps201530_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4: 368\u201381.","journal-title":"WHO Study Group. Osteoporos Int"},{"key":"BFaps201530_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/aps.2012.12","volume":"33","author":"H Yue","year":"2012","unstructured":"Yue H, He JW, Zhang H, Wang C, Hu WW, Gu JM, et al. Contribution of myostatin gene polymorphisms to normal variation in lean mass, fat mass and peak BMD in Chinese male offspring. Acta Pharmacol Sin 2012; 33: 660\u20137.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps201530_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137\u201348.","journal-title":"J Bone Miner Res"},{"key":"BFaps201530_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/aps.2011.172","volume":"33","author":"H Zhang","year":"2012","unstructured":"Zhang H, Huang QR, Gu JM, Hu WW, Liu YJ, Hu YQ, et al. Comparison of the effects of cholecalciferol and calcitriol on calcium metabolism and bone turnover in Chinese postmenopausal women with vitamin D insufficiency. Acta Pharmacol Sin 2012; 33: 490\u20135.","journal-title":"Acta Pharmacol Sin"},{"key":"BFaps201530_CR10","first-page":"1965","volume":"29","author":"AB Thomson","year":"2002","unstructured":"Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, et al. Forteen day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002; 29: 1965\u201374.","journal-title":"J Rheumatol"},{"key":"BFaps201530_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00223-010-9401-0","volume":"87","author":"SH Ralston","year":"2010","unstructured":"Ralston SH, Kou TD, Wick-Urban B, Steinbuch M, Masud T . Risk of upper gastrointestinal tract events in risedronate users switched to alendronate. Calcif Tissue Int 2010; 87: 298\u2013304.","journal-title":"Calcif Tissue Int"},{"key":"BFaps201530_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00198-007-0531-9","volume":"19","author":"PD Delmas","year":"2008","unstructured":"Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19: 1039\u201345.","journal-title":"Osteoporos Int"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201530","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:07Z","timestamp":1684413187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFaps201530"],"URL":"https:\/\/doi.org\/10.1038\/aps.2015.30","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]},"assertion":[{"value":"2 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}